FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which “Side” Are You On?

Irene S. Yu, Jonathan M. Loree

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which “Side” Are You On?'. Together they form a unique fingerprint.

Medicine & Life Sciences